{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:40:54Z","timestamp":1762641654301},"reference-count":25,"publisher":"American Diabetes Association","issue":"9","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,9,1]]},"abstract":"<jats:p>This study tried to replicate in a large sample of white patients with type 2 diabetes (T2D) from Italy a previously reported association of the IRS1 G972R polymorphism with failure to oral antidiabetes drugs (OAD). A total of 2,409 patients from four independent studies were investigated. Case subjects (n = 1,193) were patients in whom, because of uncontrolled diabetes (i.e., HbA1c &amp;gt;8%), insulin therapy had been added either on, or instead of, maximal or near-maximal doses of OAD, mostly metformin and sulfonylureas; control subjects (n = 1,216) were patients with HbA1c &amp;lt;8% in the absence of insulin therapy. The IRS1 G972R polymorphism was typed by TaqMan allele discrimination. In all samples, individuals carrying the IRS1 R972 risk variant tended to be more frequent among case than control subjects, though reaching statistical significance only in one case. As no IRS1 G972R-by-study sample interaction was observed, data from the four samples were analyzed together; a significant association was observed (allelic odds ratio [OR] 1.30, 95% CI 1.03\u20131.63). When our present data were meta-analyzed with those obtained in a previous study, an overall R972 allelic OR of 1.37 (1.12\u20131.69) was observed. This study confirms in a large and ethnically homogeneous sample that IRS1 G972R polymorphism is associated with failure to OAD among patients with T2D.<\/jats:p>","DOI":"10.2337\/db13-1966","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T06:59:58Z","timestamp":1403247598000},"page":"3135-3140","update-policy":"http:\/\/dx.doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":16,"title":["<i>IRS1<\/i> G972R Missense Polymorphism Is Associated With Failure to Oral Antidiabetes Drugs in White Patients With Type 2 Diabetes From Italy"],"prefix":"10.2337","volume":"63","author":[{"given":"Sabrina","family":"Prudente","sequence":"first","affiliation":[{"name":"Mendel Laboratory, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Morini","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Lucchesi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Lamacchia","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Bailetti","sequence":"additional","affiliation":[{"name":"Mendel Laboratory, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy"},{"name":"Department of Experimental Medicine, Sapienza University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luana","family":"Mercuri","sequence":"additional","affiliation":[{"name":"Mendel Laboratory, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Alberico","sequence":"additional","affiliation":[{"name":"Mendel Laboratory, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Copetti","sequence":"additional","affiliation":[{"name":"Unit of Biostatistics, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pucci","sequence":"additional","affiliation":[{"name":"Institute of Agricultural Biology and Biotechnology, CNR, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Fariello","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Giusti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Cignarelli","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Penno","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"De Cosmo","sequence":"additional","affiliation":[{"name":"Clinical Unit of Endocrinology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Trischitta","sequence":"additional","affiliation":[{"name":"Mendel Laboratory, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy"},{"name":"Department of Experimental Medicine, Sapienza University, Rome, Italy"},{"name":"Research Unit of Diabetes and Endocrine Diseases, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2014,8,16]]},"reference":[{"key":"2022031223031048500_B1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","article-title":"IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030","volume":"94","author":"Whiting","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031223031048500_B2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031223031048500_B3","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1210\/jc.2009-1966","article-title":"Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know","volume":"95","author":"Smith","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031223031048500_B4","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031223031048500_B5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2337\/dc13-0512","article-title":"Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors\u2019 Expert Forum","volume":"36","author":"Raz","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031223031048500_B6","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031223031048500_B7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/gm292","article-title":"Pharmacogenetics in type 2 diabetes: potential implications for clinical practice","volume":"3","author":"Huang","year":"2011","journal-title":"Genome Med"},{"key":"2022031223031048500_B8","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2337\/diacare.27.6.1394","article-title":"The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes","volume":"27","author":"Sesti","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031223031048500_B9","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1093\/ndt\/gfs148","article-title":"The 9p21 coronary artery disease locus and kidney dysfunction in patients with type 2 diabetes mellitus","volume":"27","author":"De Cosmo","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2022031223031048500_B10","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s00125-010-2037-9","article-title":"Relationship between ADIPOQ gene, circulating high molecular weight adiponectin and albuminuria in individuals with normal kidney function: evidence from a family-based study","volume":"54","author":"Menzaghi","year":"2011","journal-title":"Diabetologia"},{"key":"2022031223031048500_B11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.evalprogplan.2005.01.004","article-title":"Estimating causal effects of public health education campaigns using propensity score methodology","volume":"28","author":"Yanovitzky","year":"2005","journal-title":"Eval Program Plann"},{"key":"2022031223031048500_B12","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031223031048500_B13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40291-012-0002-7","article-title":"Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data","volume":"16","author":"Mannino","year":"2012","journal-title":"Mol Diagn Ther"},{"key":"2022031223031048500_B14","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1007\/s00125-009-1426-4","article-title":"IRS1 G972R polymorphism and type 2 diabetes: a paradigm for the difficult ascertainment of the contribution to disease susceptibility of \u2018low-frequency-low-risk\u2019 variants","volume":"52","author":"Morini","year":"2009","journal-title":"Diabetologia"},{"key":"2022031223031048500_B15","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1096\/fj.01-0009rev","article-title":"Defects of the insulin receptor substrate (IRS) system in human metabolic disorders","volume":"15","author":"Sesti","year":"2001","journal-title":"FASEB J"},{"key":"2022031223031048500_B16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(95)92779-4","article-title":"Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1","volume":"346","author":"Clausen","year":"1995","journal-title":"Lancet"},{"key":"2022031223031048500_B17","doi-asserted-by":"crossref","first-page":"882","DOI":"10.2337\/diabetes.50.4.882","article-title":"The Gly972Arg polymorphism in the insulin receptor substrate-1 gene contributes to the variation in insulin secretion in normal glucose-tolerant humans","volume":"50","author":"Stumvoll","year":"2001","journal-title":"Diabetes"},{"key":"2022031223031048500_B18","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s00125-003-1126-4","article-title":"Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies","volume":"46","author":"Jellema","year":"2003","journal-title":"Diabetologia"},{"key":"2022031223031048500_B19","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/ng.443","article-title":"Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia","volume":"41","author":"Rung","year":"2009","journal-title":"Nat Genet"},{"key":"2022031223031048500_B20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ng.609","article-title":"Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis","volume":"42","author":"Voight","year":"2010","journal-title":"Nat Genet"},{"key":"2022031223031048500_B21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/ng.520","article-title":"New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk","volume":"42","author":"Dupuis","year":"2010","journal-title":"Nat Genet"},{"key":"2022031223031048500_B22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/ng.2274","article-title":"A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance","volume":"44","author":"Manning","year":"2012","journal-title":"Nat Genet"},{"key":"2022031223031048500_B23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ng.2385","article-title":"Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways","volume":"44","author":"Scott","year":"2012","journal-title":"Nat Genet"},{"key":"2022031223031048500_B24","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.2337\/diabetes.53.12.3313","article-title":"Association testing in 9,000 people fails to confirm the association of the insulin receptor substrate-1 G972R polymorphism with type 2 diabetes","volume":"53","author":"Florez","year":"2004","journal-title":"Diabetes"},{"key":"2022031223031048500_B25","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.2337\/diabetes.53.12.3319","article-title":"Association studies of insulin receptor substrate 1 gene (IRS1) variants in type 2 diabetes samples enriched for family history and early age of onset","volume":"53","author":"Zeggini","year":"2004","journal-title":"Diabetes"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/63\/9\/3135\/576228\/3135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/63\/9\/3135\/576228\/3135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:40:24Z","timestamp":1667407224000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/63\/9\/3135\/34687\/IRS1-G972R-Missense-Polymorphism-Is-Associated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,16]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,8,16]]},"published-print":{"date-parts":[[2014,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db13-1966","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,16]]}}}